NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
Clinical Trials
64 trialsNCT07340541 2026-04-13
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06244004 2026-03-30
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT07490210 2026-03-24
OMPC-RPM
Fudan University
Phase 2 Not yet recruiting
NCT07476001 2026-03-17
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT05726292 2026-03-04
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
Phase 2 Recruiting
NCT01409200 2026-03-03
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05676463 2026-03-03
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT04126070 2026-01-22
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03456843 2026-01-21
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
Yale University
Phase 2 Active not recruiting
NCT04267887 2026-01-20
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT07313241 2025-12-31
(RANGER)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07310433 2025-12-30
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
The University of Hong Kong
Phase 2 Not yet recruiting
NCT07268794 2025-12-08
CONVERT-HB1
Fudan University
Phase 2 Not yet recruiting
NCT06150417 2025-11-12
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03541850 2025-11-06
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05100472 2025-11-04
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07216248 2025-10-29
OPTIMAS
University of Utah
Phase 2 Recruiting
NCT06834321 2025-09-08
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
Zhongda Hospital
Phase 2 Recruiting
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT06392295 2025-06-15
OCEAN
University of Miami
Phase 2 Recruiting
NCT05790213 2025-06-12
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
University of Chicago
Phase 2 Recruiting
NCT06312670 2025-05-29
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT06992232 2025-05-28
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06765954 2025-05-06
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT04743934 2025-05-04
RAD 2003
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT06212583 2025-05-01
KNIGHTS
University of Maryland, Baltimore
Phase 2 Recruiting
NCT04298983 2025-03-19
RAD 1805
University of Alabama at Birmingham
Phase 2 Terminated
NCT06582446 2025-03-11
HypoElect
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT06818682 2025-02-21
RELAX
Tata Memorial Centre
Phase 2 Recruiting
NCT06772441 2025-01-13
HypoPro
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT03569241 2024-12-09
STORM
University Hospital, Ghent
Phase 2 Active not recruiting
NCT05404139 2024-11-25
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT06500247 2024-07-15
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
Qilu Hospital of Shandong University
Phase 2 Not yet recruiting
NCT04465500 2024-05-13
Prostate005
University of Virginia
Phase 2 Recruiting
NCT06305832 2024-03-12
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05851547 2024-01-05
DEFINE
Ottawa Hospital Research Institute
Phase 2 Recruiting
NCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT03940235 2023-06-28
RADIOSA
European Institute of Oncology
Phase 2 Unknown
NCT05778097 2023-03-21
ARES
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT05753566 2023-03-06
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting